Datasets
Our registries are built in partnership with community specialty providers, capturing longitudinal clinical depth not found in legacy data sources.
Our registries are built in partnership with community specialty providers, capturing longitudinal clinical depth not found in legacy data sources.
Registry datasets are analysis-ready in OMOP CDM format, compatible with your existing analytics environment, with variable-level traceability back to source data.
Registry datasets are analysis-ready in OMOP CDM format, compatible with your existing analytics environment, with variable-level traceability back to source data.
Therapeutic Areas
All
Metabolic
Neurology
Immunology
Ophthalmology
Renal
Respiratory
Asthma
Respiratory
Key Variables
Structured:
FEV1, FEV1/FVC ratio
Eosinophil count, IgE & FeNO
Oral corticosteroid bursts
ED visits & hospitalisations
Biologic agent & start date
ICS/LABA & LAMA regimen
Comorbidities
Abstracted with AI:
Asthma severity classification
Allergy test results
Smoking status & pack-years
Insights
T2 vs. non-T2 biologic response
Biologic switching patterns & drivers
Early biologic impact on OCS dependence
Exacerbation risk by phenotype
Chronic Kidney Disease
Renal
Key Variables
Structured:
CKD stage (1–5 / ESKD)
eGFR & eGFR slope
UACR & UPCR
SGLT2 inhibitor use
RAAS agent use
MRA use
Immunosuppressive therapy
Comorbidities
Abstracted with AI:
Glomerular disease subtype
Biopsy findings (chronicity, % crescents)
Insights
SGLT2 & finerenone real-world eGFR outcomes
GN subtype progression & treatment response
Pathways to dialysis & transplant
Proteinuria reduction by therapy class
Diabetic Retinopathy
Ophthalmology
Key Variables
Structured:
DR severity stage
DME status
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Systemic diabetes medications
Comorbidities
Abstracted by AI:
IRF, SRF, CME & hyperreflective foci
Ellipsoid zone integrity
Fibrosis & macular scarring
Neovascularization (NVD/NVE)
Foveal avascular zone size
Insights
NPDR-to-PDR progression predictors
Anti-VEGF response & treatment intervals
Systemic disease control & visual outcomes
DME development & resolution patterns
Alzheimer's Disease
Neurology
Key Variables
Structured:
CSF & blood biomarkers (Aβ42, tau, p-tau, NfL)
APOE genotype
Anti-amyloid therapy & start date
Cholinesterase inhibitors & memantine
Comorbidities
Abstracted with AI:
MMSE, MoCA, ADAS-Cog
CDR & FAST staging
Neuropsychiatric symptom scores
Disease stage & severity
ARIA incidence
Amyloid & tau PET findings
MRI findings
Insights
Cognitive trajectories by biomarker profile
Real-world ARIA rates & management
Anti-amyloid therapy persistence & discontinuation
Early vs. late treatment initiation outcomes
IBD
Immunology
Key Variables
Structured:
Subtype
Disease behavior
Biologic use & start date
JAK inhibitor use
Immunomodulator use
Corticosteroid use
CRP, ESR, fecal calprotectin
Surgical procedure type & date
Comorbidities
Abstracted with AI:
Mayo Endoscopic Score
SES-CD score
Harvey-Bradshaw Index / CDAI
Disease location & extent
Stricture, fistula & abscess presence
Insights
Biologic & JAK inhibitor sequencing patterns
Drug monitoring & dose optimization
Disease behavior progression & surgery risk
Endoscopic vs. clinical remission rates
COPD
Respiratory
Key Variables
Structured:
FEV1, FEV1/FVC ratio
Eosinophil count
Oral corticosteroid bursts
Inhaled therapy regimen
ED visits & hospitalisations
Biologic agent & start date
Comorbidities
Abstracted with AI:
GOLD classification
Emphysema distribution & bronchiectasis
Smoking status & pack-years
Insights
Exacerbation risk by GOLD stage & phenotype
Eosinophil-guided biologic response
Triple therapy adoption & outcomes
OCS dependence & cumulative burden
Age-Related Macular Degeneration
Ophthalmology
Key Variables
Structured:
AMD subtype
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Comorbidities
Abstracted with AI:
IRF, SRF, PED & SHRM
Ellipsoid zone integrity
Geographic atrophy extent
Fibrosis & macular scarring
CNV presence & type
Drusen & pigmentary changes
Insights
Predictors of dry-to-wet conversion
Anti-VEGF treatment intervals & switching
GA progression by subtype & location
Fibrosis & vision loss trajectories
Multiple Sclerosis
Neurology
Key Variables
Structured:
JCV antibody results
Infection events
Lymphocyte counts & safety labs
Encounter frequency & visit cadence
Comorbidities
Abstracted with AI:
Estimated EDSS
Relapse events
MRI results & progression
DMT agent, initiation & discontinuation reason
DMT prescription date
Infusion dates
Concomitant medications
Patient-reported symptoms
Insights
DMT switching patterns & outcomes
High- vs. moderate-efficacy therapy sequences
Relapse frequency & disability progression
Real-world DMT discontinuation & persistence
MASH
Metabolic
Key Variables
Structured:
ALT, AST, GGT, bilirubin
FIB-4, APRI
HbA1c, fasting glucose
Lipid panel
BMI & weight
GLP-1 agonist use
SGLT2 inhibitor use
Comorbidities
Abstracted with AI:
Fibrosis stage
Steatosis severity
NAS score
FibroScan (kPa, CAP score)
MRI-PDFF
Ascites & signs of cirrhosis
Insights
Fibrosis progression predictors
GLP-1 & SGLT2 real-world response
Metabolic comorbidity burden & outcomes
Treatment initiation timing & patterns
Asthma
Respiratory
Key Variables
Structured:
FEV1, FEV1/FVC ratio
Eosinophil count, IgE & FeNO
Oral corticosteroid bursts
ED visits & hospitalisations
Biologic agent & start date
ICS/LABA & LAMA regimen
Comorbidities
Abstracted with AI:
Asthma severity classification
Allergy test results
Smoking status & pack-years
Insights
T2 vs. non-T2 biologic response
Biologic switching patterns & drivers
Early biologic impact on OCS dependence
Exacerbation risk by phenotype
COPD
Respiratory
Key Variables
Structured:
FEV1, FEV1/FVC ratio
Eosinophil count
Oral corticosteroid bursts
Inhaled therapy regimen
ED visits & hospitalisations
Biologic agent & start date
Comorbidities
Abstracted with AI:
GOLD classification
Emphysema distribution & bronchiectasis
Smoking status & pack-years
Insights
Exacerbation risk by GOLD stage & phenotype
Eosinophil-guided biologic response
Triple therapy adoption & outcomes
OCS dependence & cumulative burden
Chronic Kidney Disease
Renal
Key Variables
Structured:
CKD stage (1–5 / ESKD)
eGFR & eGFR slope
UACR & UPCR
SGLT2 inhibitor use
RAAS agent use
MRA use
Immunosuppressive therapy
Comorbidities
Abstracted with AI:
Glomerular disease subtype
Biopsy findings (chronicity, % crescents)
Insights
SGLT2 & finerenone real-world eGFR outcomes
GN subtype progression & treatment response
Pathways to dialysis & transplant
Proteinuria reduction by therapy class
Age-Related Macular Degeneration
Ophthalmology
Key Variables
Structured:
AMD subtype
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Comorbidities
Abstracted with AI:
IRF, SRF, PED & SHRM
Ellipsoid zone integrity
Geographic atrophy extent
Fibrosis & macular scarring
CNV presence & type
Drusen & pigmentary changes
Insights
Predictors of dry-to-wet conversion
Anti-VEGF treatment intervals & switching
GA progression by subtype & location
Fibrosis & vision loss trajectories
Diabetic Retinopathy
Ophthalmology
Key Variables
Structured:
DR severity stage
DME status
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Systemic diabetes medications
Comorbidities
Abstracted by AI:
IRF, SRF, CME & hyperreflective foci
Ellipsoid zone integrity
Fibrosis & macular scarring
Neovascularization (NVD/NVE)
Foveal avascular zone size
Insights
NPDR-to-PDR progression predictors
Anti-VEGF response & treatment intervals
Systemic disease control & visual outcomes
DME development & resolution patterns
Multiple Sclerosis
Neurology
Key Variables
Structured:
JCV antibody results
Infection events
Lymphocyte counts & safety labs
Encounter frequency & visit cadence
Comorbidities
Abstracted with AI:
Estimated EDSS
Relapse events
MRI results & progression
DMT agent, initiation & discontinuation reason
DMT prescription date
Infusion dates
Concomitant medications
Patient-reported symptoms
Insights
DMT switching patterns & outcomes
High- vs. moderate-efficacy therapy sequences
Relapse frequency & disability progression
Real-world DMT discontinuation & persistence
Alzheimer's Disease
Neurology
Key Variables
Structured:
CSF & blood biomarkers (Aβ42, tau, p-tau, NfL)
APOE genotype
Anti-amyloid therapy & start date
Cholinesterase inhibitors & memantine
Comorbidities
Abstracted with AI:
MMSE, MoCA, ADAS-Cog
CDR & FAST staging
Neuropsychiatric symptom scores
Disease stage & severity
ARIA incidence
Amyloid & tau PET findings
MRI findings
Insights
Cognitive trajectories by biomarker profile
Real-world ARIA rates & management
Anti-amyloid therapy persistence & discontinuation
Early vs. late treatment initiation outcomes
MASH
Metabolic
Key Variables
Structured:
ALT, AST, GGT, bilirubin
FIB-4, APRI
HbA1c, fasting glucose
Lipid panel
BMI & weight
GLP-1 agonist use
SGLT2 inhibitor use
Comorbidities
Abstracted with AI:
Fibrosis stage
Steatosis severity
NAS score
FibroScan (kPa, CAP score)
MRI-PDFF
Ascites & signs of cirrhosis
Insights
Fibrosis progression predictors
GLP-1 & SGLT2 real-world response
Metabolic comorbidity burden & outcomes
Treatment initiation timing & patterns
IBD
Immunology
Key Variables
Structured:
Subtype
Disease behavior
Biologic use & start date
JAK inhibitor use
Immunomodulator use
Corticosteroid use
CRP, ESR, fecal calprotectin
Surgical procedure type & date
Comorbidities
Abstracted with AI:
Mayo Endoscopic Score
SES-CD score
Harvey-Bradshaw Index / CDAI
Disease location & extent
Stricture, fistula & abscess presence
Insights
Biologic & JAK inhibitor sequencing patterns
Drug monitoring & dose optimization
Disease behavior progression & surgery risk
Endoscopic vs. clinical remission rates
Asthma
Respiratory
Key Variables
Structured:
FEV1, FEV1/FVC ratio
Eosinophil count, IgE & FeNO
Oral corticosteroid bursts
ED visits & hospitalisations
Biologic agent & start date
ICS/LABA & LAMA regimen
Comorbidities
Abstracted with AI:
Asthma severity classification
Allergy test results
Smoking status & pack-years
Insights
T2 vs. non-T2 biologic response
Biologic switching patterns & drivers
Early biologic impact on OCS dependence
Exacerbation risk by phenotype
COPD
Respiratory
Key Variables
Structured:
FEV1, FEV1/FVC ratio
Eosinophil count
Oral corticosteroid bursts
Inhaled therapy regimen
ED visits & hospitalisations
Biologic agent & start date
Comorbidities
Abstracted with AI:
GOLD classification
Emphysema distribution & bronchiectasis
Smoking status & pack-years
Insights
Exacerbation risk by GOLD stage & phenotype
Eosinophil-guided biologic response
Triple therapy adoption & outcomes
OCS dependence & cumulative burden
Chronic Kidney Disease
Renal
Key Variables
Structured:
CKD stage (1–5 / ESKD)
eGFR & eGFR slope
UACR & UPCR
SGLT2 inhibitor use
RAAS agent use
MRA use
Immunosuppressive therapy
Comorbidities
Abstracted with AI:
Glomerular disease subtype
Biopsy findings (chronicity, % crescents)
Insights
SGLT2 & finerenone real-world eGFR outcomes
GN subtype progression & treatment response
Pathways to dialysis & transplant
Proteinuria reduction by therapy class
Age-Related Macular Degeneration
Ophthalmology
Key Variables
Structured:
AMD subtype
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Comorbidities
Abstracted with AI:
IRF, SRF, PED & SHRM
Ellipsoid zone integrity
Geographic atrophy extent
Fibrosis & macular scarring
CNV presence & type
Drusen & pigmentary changes
Insights
Predictors of dry-to-wet conversion
Anti-VEGF treatment intervals & switching
GA progression by subtype & location
Fibrosis & vision loss trajectories
Diabetic Retinopathy
Ophthalmology
Key Variables
Structured:
DR severity stage
DME status
Visual acuity
CST & macular volume
Anti-VEGF agent & injection date
Systemic diabetes medications
Comorbidities
Abstracted by AI:
IRF, SRF, CME & hyperreflective foci
Ellipsoid zone integrity
Fibrosis & macular scarring
Neovascularization (NVD/NVE)
Foveal avascular zone size
Insights
NPDR-to-PDR progression predictors
Anti-VEGF response & treatment intervals
Systemic disease control & visual outcomes
DME development & resolution patterns
Multiple Sclerosis
Neurology
Key Variables
Structured:
JCV antibody results
Infection events
Lymphocyte counts & safety labs
Encounter frequency & visit cadence
Comorbidities
Abstracted with AI:
Estimated EDSS
Relapse events
MRI results & progression
DMT agent, initiation & discontinuation reason
DMT prescription date
Infusion dates
Concomitant medications
Patient-reported symptoms
Insights
DMT switching patterns & outcomes
High- vs. moderate-efficacy therapy sequences
Relapse frequency & disability progression
Real-world DMT discontinuation & persistence
Alzheimer's Disease
Neurology
Key Variables
Structured:
CSF & blood biomarkers (Aβ42, tau, p-tau, NfL)
APOE genotype
Anti-amyloid therapy & start date
Cholinesterase inhibitors & memantine
Comorbidities
Abstracted with AI:
MMSE, MoCA, ADAS-Cog
CDR & FAST staging
Neuropsychiatric symptom scores
Disease stage & severity
ARIA incidence
Amyloid & tau PET findings
MRI findings
Insights
Cognitive trajectories by biomarker profile
Real-world ARIA rates & management
Anti-amyloid therapy persistence & discontinuation
Early vs. late treatment initiation outcomes
MASH
Metabolic
Key Variables
Structured:
ALT, AST, GGT, bilirubin
FIB-4, APRI
HbA1c, fasting glucose
Lipid panel
BMI & weight
GLP-1 agonist use
SGLT2 inhibitor use
Comorbidities
Abstracted with AI:
Fibrosis stage
Steatosis severity
NAS score
FibroScan (kPa, CAP score)
MRI-PDFF
Ascites & signs of cirrhosis
Insights
Fibrosis progression predictors
GLP-1 & SGLT2 real-world response
Metabolic comorbidity burden & outcomes
Treatment initiation timing & patterns
IBD
Immunology
Key Variables
Structured:
Subtype
Disease behavior
Biologic use & start date
JAK inhibitor use
Immunomodulator use
Corticosteroid use
CRP, ESR, fecal calprotectin
Surgical procedure type & date
Comorbidities
Abstracted with AI:
Mayo Endoscopic Score
SES-CD score
Harvey-Bradshaw Index / CDAI
Disease location & extent
Stricture, fistula & abscess presence
Insights
Biologic & JAK inhibitor sequencing patterns
Drug monitoring & dose optimization
Disease behavior progression & surgery risk
Endoscopic vs. clinical remission rates